Synthesis of some benzimidazole derivatives endowed with 1,2,3-triazole as potential inhibitors of hepatitis C virus

1. J. S. Au and P. J. Pockros, Novel therapeutic approaches for hepatitis C, Clin. Pharmacol. Ther. 95 (2014) 78–88; DOI: 10.1038/clpt.2013.206.10.1038/clpt.2013.206Search in Google Scholar

2. M. P. Manns, J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling and J. K. Albrecht, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet358 (2001) 958–965.10.1016/S0140-6736(01)06102-5Search in Google Scholar

3. M. W. Fried, M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Gonçales Jr., D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman and J. Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med.347 (2002) 975–982; DOI: 10.1056/NEJMoa020047.10.1056/NEJMoa020047Search in Google Scholar

4. Y. Bansal and O. Silakari, The therapeutic journey of benzimidazoles: A review, Bioorg. Med. Chem.20 (2012) 6208–6236; DOI: 10.1016/j.bmc.2012.09.013.10.1016/j.bmc.2012.09.013Search in Google Scholar

5. V. Boido, G. Paglietti, M. Tonelli and G. Vitale, Non-nucleoside Benzimidazoles as Antiviral Drugs Against HCV and RSV Infections, in RNA-Viruses. Enzymatic and Receptoral Inhibitors (Ed. A. Carta), Research Signpost, Kerala 2009, pp. 41–93.Search in Google Scholar

6. B. A. Katz, J. Clark, J. Finer-Moore, T. Jenkins, C. Johnson, M. Ross, C. Luong, W. Moore and R. Stroud, Design of potent selective zinc-mediated serine protease inhibitors, Nature391 (1998) 608–612; DOI: 10.1038/35422.10.1038/35422Search in Google Scholar

7. D. Sperandio, A. R. Gangloff, J. Litvak, R. Goldsmith, J. M. Hataye, V. R. Wang, E. J. Shelton, K. Elrod, J. W. Janc, J. M. Clark, K. Rice, S. Weinheimer, K. Yeung, N. A. Meanwell, D. Hernandez, A. J. Staab, B. L. Venables and J. R. Spencer, Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease, Bioorg. Med. Chem. Lett.12 (2002) 3129–3133; DOI: 10.1016/S0960-894X(02)00680-7.10.1016/S0960-894X(02)00680-7Search in Google Scholar

8. H. I. El Diwani, H. T. Abdel-Mohsen, I. Salama, F. A.-F. Ragab, M. M. Ramla, S. A. Galal, M. M. Abdalla, A. Abdel-Wahab and M. A. El Demellawy, Synthesis, molecular modeling, and biological evaluation of novel benzimidazole derivatives as inhibitors of hepatitis C virus RNA replication, Chem. Pharm. Bull.62 (2014) 856–866; DOI: 10.1248/cpb.c13-01009.10.1248/cpb.c13-01009Search in Google Scholar

9. L. Garuti, M. Roberti and G. Gentilomi, Synthesis and antiviral assays of some 2-substituted benzimidazole-N-carbamates, Farmaco55 (2000) 35–39; DOI: 10.1016/S0014-827X(99)00117-2.10.1016/S0014-827X(99)00117-2Search in Google Scholar

10. S. Budow, M. Kozlowska, A. Gorska, Z. Kazimierczuk, H. Eickmeier, P. La Colla, G. Gosselin and F. Seela, Substituted benzimidazole: antivral activity and synthesis of nucleosides, ARKIVOC iii (2009) 225–250; DOI: 10.3998/ark.5550190.0010.319.10.3998/ark.5550190.0010.319Search in Google Scholar

11. M. F. Tonelli, F. Novelli, B. Tasso, I. Vazzana, A. Sparatore, V. Boido, F. Sparatore, P. La Colla, G. Sanna, G. Giliberti, B. Busonera, P. Farci, C. Ibba and R. Loddo, Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents, Bioorg. Med. Chem.22 (2014) 4893–4909; DOI: 10.1016/j.bmc.2014.06.043.10.1016/j.bmc.2014.06.04325082514Search in Google Scholar

12. Y. Saito, V. Escuret, D. Durantel, F. Zoulim, R. F. Schinazic and L. A. Agrofoglio, Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon, Bioorg. Med. Chem.11 (2003) 3633–3639; DOI: 10.1016/S0968-0896(03)00349-3.10.1016/S0968-0896(03)00349-3Search in Google Scholar

13. F. D. Da Silva, M. C. B. V. de Souza, I. I. P. Frugulhetti, H. C. Castro, S. L. D Souza, T. M. L. de Souza, D. Q. Rodrigues, A. M. T. Souza, P. A. Abreu, F. Passamani, C. R. Rodrigues and V. F. Ferreira, Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates, Eur. J. Med. Chem.44 (2009) 373–383; DOI: 10.1016/j.ejmech.2008.02.047.10.1016/j.ejmech.2008.02.047Search in Google Scholar

14. D. K. Mohapatra, P. K. Maity, M. Shabab and M. I. Khan, Click chemistry based rapid one-pot synthesis and evaluation for protease inhibition of new tetracyclic triazole fused benzodiazepine derivatives, Bioorg. Med. Chem.19 (2009) 5241–5245; DOI: 10.1016/j.bmcl.2009.06.107.10.1016/j.bmcl.2009.06.107Search in Google Scholar

15. T. O. Olomola, R. Klein, K. A. Lobb, Y. Sayed and P. T. Kaye, Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors, Bioorg. Med. Chem.21 (2013) 1964–1971; DOI: 10.1016/j.bmc.2013.01.025.10.1016/j.bmc.2013.01.025Search in Google Scholar

16. M. M. Heravi, A. Keivanloo, M. Rahimizadeh, M. Bakavoli and M. Ghassemzadeh, Pd–Cu catalyzed heterocyclization during Sonogashira coupling: synthesis of 3-benzylthiazolo[3,2-a]benzimidazole, Tetrahedron Lett.45 (2004) 5747–5749; DOI: 10.1016/j.tetlet.2004.05.094.10.1016/j.tetlet.2004.05.094Search in Google Scholar

17. K.-C. Tiew, D. Dou, T. Teramoto, H. Lai, K. R. Alliston, G. H. Lushington, R. Padmanabhan and W. C. Groutas, Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d] isothiazol-3(2H)-one derivatives, Bioorg. Med. Chem.20 (2012) 1213–1221; DOI: 10.1016/j.bmc.2011.12.047.10.1016/j.bmc.2011.12.047Search in Google Scholar

18. C. Baba, K. Yanagida, T. Kanzaki and M. Baba, Colorimetric lactate dehydrogenase (LDH) assay for evaluation of antiviral activity against bovine viral diarrhoea virus (BVDV) in vitro, Antivir. Chem. Chemother.16 (2005) 33–39; DOI: 10.1016/j.biomaterials.2014.01.054.10.1016/j.biomaterials.2014.01.054Search in Google Scholar

19. K. Sako, H. Aoyama, S. Sato, Y. Hashimoto and M. Baba, γ-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity, Bioorg. Med. Chem.16 (2008) 3780–3790; DOI: 10.1016/j.bmc.2008.01.052.10.1016/j.bmc.2008.01.052Search in Google Scholar

20. H. C. Kolb, M. G. Finn and K. B. Sharpless, Click chemistry: Diverse chemical function from a few good reactions, Angew. Chem. Int. Ed.40 (2001) 2004–2021; DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5.10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5Search in Google Scholar

21. J. E. Moses and A. D. Moorhouse, The growing applications of click chemistry, Chem. Soc. Rev.36 (2007) 1249–1262; DOI: 10.1039/b613014n.10.1039/B613014NSearch in Google Scholar

22. S. G. Agalave, S. R. Maujan and V. S. Pore, Click chemistry: 1,2,3-Triazoles as pharmacophores, Chem. Asian J.6 (2011) 2696–2718; DOI: 10.1002/asia.201100432.10.1002/asia.20110043221954075Search in Google Scholar

23. J.-F. Lutz and Z. Zarafshani, Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne “click” chemistry, Adv. Drug Deliv. Rev.60 (2008) 958–970; DOI: 10.1016/j.addr.2008.02.004.10.1016/j.addr.2008.02.00418406491Search in Google Scholar

24. K. Lin, R. B. Perni, A. D. Kwong and c. Lin, VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells, Antimicrob. Agents. Cli.50 (2006) 1813–1822; DOI: 10.1128/AAC.50.5.1813-1822.2006.10.1128/AAC.50.5.1813-1822.2006147222716641454Search in Google Scholar

25. J. G. Topliss, Utilization of operational schemes for analog synthesis in drug design, J. Med. Chem.15 (1972) 1006–1011; DOI: 10.1021/jm00280a002.10.1021/jm00280a0025069767Search in Google Scholar

26. J. G. Topliss, A manual method for applying the Hansch approach to drug design, J. Med. Chem.20 (1977) 463–469; DOI: 10.1021/jm00214a001.10.1021/jm00214a001321782Search in Google Scholar